Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

Regulatory

October 23, 2025

Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on currently available clinical data

Read more

October 15, 2025

Egetis and taiba rare Sign Exclusive Distribution and Early Access Agreement to Enable Named Patient Sales of Emcitate® in the Gulf Region

Read more

October 10, 2025

Egetis’ Nomination Committee for the 2026 Annual General Meeting

Read more

Upcoming event

November 12, 2025

Stifel Annual Healthcare Conference (New York)

Latest presentation

October 23, 2025

Egetis granted rolling NDA review (webcast)

Latest Report

August 21, 2025

Interim report Q2 2025

Calendar and upcoming reports

November 11-13, 2025

Stifel Annual Healthcare Conference (New York)

November 17, 2025

LifeSci Capital & Sofinnova, Growth & Innovation Summit (London)

November 25, 2025 (7:00am CET)

Interim Report Q3 2025

November 25, 2025

DNB Carnegie Nordic Healthcare Conference (Oslo)

January 12-13, 2026

JP Morgan Healthcare Week (San Francisco, CA)

February 26, 2026 (7:00am CET)

Year-end Report Q4 2025

March 8-11, 2026

Leerink Global Healthcare Conference (Miami, FL)

March 11-12, 2026

DNB Carnegie Healthcare Conference (Stockholm)

April 29, 2026 (7:00am CEST)

Interim Report Q1 2026

May 6, 2026

Annual General Meeting

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]